X

Posts

November 19, 2012

+
2:00 PM | Why Sanofi’s Zaltrap Deal Won’t Help Patients
I got excited when I read the New York Times story Nov. 9 (“Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection)”. Zaltrap is an intravenous infusion colon cancer drug for metastatic colorectal cancer that is resistant to or has progressed with platinum-based chemotherapy. With a list price of $11,000 per patient per month, [...]

August 10, 2012

+
4:09 PM | Global Drug Companies Go for Gold with Aggressive Insulin Analogue Marketing
While nations and athletes compete briefly on a world stage for Olympic gold, three recent articles in the BMJ remind us that pharmaceutical companies compete across the world for real gold. For instance, the worldwide market for insulin is huge and the papers question the ethics of global pharmaceutical companies. Sanofi-Aventis, Novo-Nordisk, and Eli Lilly [...]
1
2 Results